X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Merck Sees 80 Plus Cancer Patents By 2028 Led By Keytruda

Content Team by Content Team
10th June 2022
in Manufacturing, Middle East and South Asia, News
FDA Approves Expanded Indication for Merck's KEYTRUDA in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Merck & Co. was not at all a prominent oncology player before the advent of Keytruda. The New Jersey drugmaker wants to consolidate its supremacy now that it has the world’s best-selling cancer medication. Jannie Oosthuizen, Merck’s head of global oncology, told investors at an event at the 2022 American Society of Clinical Cancer annual meeting that Merck has the ability to gain more than 80 oncology approvals between now and 2028.

This is in addition to Merck’s oncology portfolio’s 46 currently approved indications in the United States. Keytruda has more than 30 of them, the most of any oncology drug, and Merck expects that number to rise in the coming years, according to Oosthuizen. Keytruda was the world’s best-selling cancer drug in 2021, with sales of $17.2 billion.

According to Oosthuizen, Keytruda recently passed the 1 million commercial patient mark, and its growth could surge to 2 million patients by the end of 2024.

Keytruda’s future growth will be aided by its expansion into early-stage malignancies. Keytruda has received three additional FDA clearances for use in surgery in early malignancies since last year’s ASCO, increasing its total to six. Pre-surgery and post-surgery therapy of early triple-negative breast cancer, as well as post-surgery adjuvant therapy for select kidney cancer patients and completely resected stage 2B or 2C melanoma, are among the latest signings.

Merck recently touted a success in the KEYNOTE-091 trial for Keytruda in the all-important reactive non-small cell lung cancer (NSCLC) setting for prospective near-term regulatory requirements. It also expects results from the phase 3 KEYNOTE-671 trial, which is evaluating Keytruda as a neoadjuvant and adjuvant treatment for NSCLC patients in stages 2 to 2B.

Between 2022 and 2025, Merck is conducting 14 Keytruda phase 3 trials in early-stage illnesses. According to those figures, Merck anticipates early-phase settings to account for around 25% of overall Keytruda revenue by 2025, as per Oosthuizen. Merck CEO Rob Davis estimated the early-stage fraction at 30% during the company’s fourth-quarter results call in February. Davis was referring to Keytruda’s revenue in the United States.

An FDA clearance, however, will not be enough to break into the early-stage market, according to Oosthuizen. At the commercial organisation, they are working to guarantee that the whole breadth and capabilities of the organisation are meeting the needs of its customers by successfully delivering necessary details to them when they need it and in the route they prefer, the executive added.

Oosthuizen believes this is critical in the early-stage scenario. Merck is working on an under-the-skin form of Keytruda for this purpose. He added that the company is using digital marketing to help with its commercial execution. New tumour types, early lines of therapy—including adjuvant and neoadjuvant—new mechanisms, combinations, and formulations will all be major growth drivers in Merck’s broader oncology agenda, according to Oosthuizen.

Merck is keeping an eye on some prominent immunotherapy targets, such as CTLA-4, LAG-3, and TIGIT, for possible pairings with Keytruda. Lynparza, which is paired with AstraZeneca; Lenvima, which is shared with Eisai; and Tukysa, which is partnered with Seagen- are in clinical trials with Keytruda.

In terms of new mechanisms, Merck’s Welireg was approved by the FDA last year to help patients with rare von Hippel-Lindau disease-related cancers. It’s the first HIF-2alpha inhibitor approved in the United States. Merck is also testing the medicine in diverse renal disease scenarios as a single therapy in combination with Lenvima, both with and without Keytruda.

Previous Post

Bispecific Blood Cancer Drug By Roche Globally Approved

Next Post

Alnylam Gives Findings of siRNA Delivery Outside of Liver

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Alnylam Gives Findings of siRNA Delivery Outside of Liver

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In